Initial Treatment
All patients received WLE in accordance with the National Comprehensive Cancer Network (NCCN) surgical management of melanoma guidelines. Of the nineteen patients who underwent a sentinel lymph node biopsy (SLNB) at the time of WLE, 11 had a positive SLN (57.9%). Of these 19 patients, 6 received nivolumab, 1 received interferon alpha-2b, and 1 received tremelimumab within 90 days of the WLE. Out of the three patients with ulceration, two received nivolumab. Eighteen patients were considered in complete remission (CR) following their initial treatment. Two patients had recurrence of their melanoma (at 10 and 19 months from WLE) and 2 other patients were still undergoing initial nivolumab treatment at the time of the writing of this article. The patients (n=6) whose initial therapy included nivolumab in addition to WLE did not show recurrence or progression of their disease. Out of the 6 patients who received nivolumab therapy, 4 had no adverse events (66.7%), 1 had a grade 3 lichenoid drug eruption (leading to treatment discontinuation) and 1 had peripheral eosinophilia (prompting treatment withholding for 1 month).